PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF THE BISPECIFIC T-CELL ENGAGER ANTIBODY BLINATUMOMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Hijazi, Y. [1 ]
Klinger, M. [1 ]
Schub, A. [1 ]
Wu, B. [2 ]
Zhu, M. [2 ]
Kufer, P. [1 ]
Wolf, A. [1 ]
Nagors-en, D. [3 ]
机构：
[1] Amgen Res Munich GmbH, Munich, Germany
[2] Pharmacokinet & Drug Metab, Thousand Oaks, CA USA
[3] Amgen Inc, Clin Dev, Thousand Oaks, CA 91320 USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P306
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
    Hijazi, Youssef
    Klinger, Matthias
    Kratzer, Andrea
    Wu, Benjamin
    Baeuerle, Patrick A.
    Kufer, Peter
    Wolf, Andreas
    Nagorsen, Dirk
    Zhu, Min
    CURRENT CLINICAL PHARMACOLOGY, 2018, 13 (01): : 55 - 64
  • [2] Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
    Goebeler, Maria-Elisabeth
    Knop, Stefan
    Viardot, Andreas
    Kufer, Peter
    Topp, Max S.
    Einsele, Hermann
    Noppeney, Richard
    Hess, Georg
    Kallert, Stefan
    Mackensen, Andreas
    Rupertus, Kathrin
    Kanz, Lothar
    Libicher, Martin
    Nagorsen, Dirk
    Zugmaier, Gerhard
    Klinger, Matthias
    Wolf, Andreas
    Dorsch, Brigitte
    Quednau, Beate D.
    Schmidt, Margit
    Scheele, Juergen
    Baeuerle, Patrick A.
    Leo, Eugen
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1104 - +
  • [3] Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis
    Yu, Jian
    Wang, Wen
    Huang, He
    HEMATOLOGY, 2019, 24 (01) : 199 - 207
  • [4] Generalizable systems pharmacology model of bispecific T-cell engager (BiTE®) antibody constructs: case study of blinatumomab (CD19/CD3) in non-Hodgkin lymphoma (NHL) patients
    Chudasama, Vaishali L.
    Harrold, John M.
    Dos Santos, Cedric
    Rock, Dan
    Kischel, Roman
    Klinger, Matthias
    Melhem, Murad
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S126 - S127
  • [5] Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL).
    Hijazi, Youssef
    Klinger, Matthias
    Schub, Andrea
    Wu, Benjamin
    Zhu, Min
    Kufer, Peter
    Wolf, Andreas
    Nagorsen, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] T-cell non-Hodgkin lymphoma
    Rizvi, MA
    Evens, AM
    Tallman, MS
    Nelson, BP
    Rosen, ST
    BLOOD, 2006, 107 (04) : 1255 - 1264
  • [7] Peripheral T-Cell Non-Hodgkin's Lymphoma
    Vose, Julie M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (05) : 997 - +
  • [8] Treatment of T-cell non-Hodgkin's lymphoma
    Evens A.M.
    Gartenhaus R.B.
    Current Treatment Options in Oncology, 2004, 5 (4) : 289 - 303
  • [9] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 71 - 72
  • [10] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 : S71 - S72
12345